Sartorius Stedim Biotech Shareholders Approve Key Resolutions

The combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. concluded with the approval of all resolutions, including the discharge of Directors. The shareholders elected Cécile Dussart and Christopher Nowers as new Board Members. Their appointments are part of the term staggering strategy, with Dussart and Nowers serving three-year terms. Existing member Joachim Kreuzburg was reappointed for two years, while René Fáber, Pascale Boissel, and Lothar Kappich will serve four-year terms.

Henri Riey, a longstanding board member since 2007, did not seek re-election. The meeting expressed gratitude for his contributions. Additionally, a dividend of 0.69 euros per share, totaling 67.1 million euros, was approved for fiscal 2024, payable from April 4, 2025.

The updated Board of Directors includes Joachim Kreuzburg as Chairman, with René Fáber as CEO, alongside other notable members. This reinforces the company's strong leadership as it continues to support the biopharmaceutical industry.